| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
127,470,000 |
| Market
Cap: |
1.66(B) |
| Last
Volume: |
878,666 |
Avg
Vol: |
1,074,261 |
| 52
Week Range: |
$11.665 - $20.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeoGenomics operate a network of cancer-focused testing laboratories in the U.S., Europe and Asia. Co.'s testing services include the following: Cytogenetics (karyotype analysis), a study of chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization, a molecular cytogenetic technique that focuses on detecting and localizing the presence or absence of specific DNA sequences and genes on chromosomes; Flow cytometry, a technique utilized to measure the characteristics of cell populations; Immunohistochemistry and Digital Imaging; Molecular testing; and Morphologic analysis, a process of analyzing cells under the microscope.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,049 |
9,748 |
12,417 |
12,417 |
| Total Sell Value |
$16,511 |
$152,803 |
$201,886 |
$201,886 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
1 |
3 |
4 |
4 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shovlin Robert J. |
President, Clinical Services |
• – – |
2021-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(742) |
147,528 |
|
- |
|
| Mckenzie Kathryn B |
Chief Financial Officer |
• – – |
2021-03-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(169) |
7,760 |
|
- |
|
| Brown Douglas Matthew |
Chief Strategy OfficerOfficer |
• – – |
2021-02-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
106,989 |
|
-17% |
|
| Jones Steven C |
Director |
– • – |
2021-01-07 |
4 |
OE |
$7.27 |
$203,835 |
D/D |
17,286 |
90,218 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2021-01-07 |
4 |
OE |
$7.15 |
$715,000 |
I/I |
100,000 |
1,100,000 |
|
- |
|
| Weiss Lawrence Martin |
Chief Medical Officer |
• – – |
2020-12-14 |
4 |
S |
$51.06 |
$1,031,412 |
D/D |
(20,200) |
100,521 |
|
1% |
|
| Weiss Lawrence Martin |
Chief Medical Officer |
• – – |
2020-12-14 |
4 |
OE |
$6.98 |
$1,024,986 |
D/D |
109,004 |
120,721 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2020-12-14 |
4 |
S |
$51.67 |
$1,291,750 |
I/I |
(25,000) |
1,000,000 |
|
1% |
|
| Jones Steven C |
Director |
– • – |
2020-12-11 |
4 |
S |
$50.52 |
$1,263,000 |
I/I |
(25,000) |
1,025,000 |
|
0% |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2020-12-11 |
4 |
S |
$49.99 |
$749,850 |
D/D |
(15,000) |
24,980 |
|
0% |
|
| Balliet Jennifer |
VP and Chief Culture Officer |
• – – |
2020-12-11 |
4 |
OE |
$8.03 |
$120,450 |
D/D |
15,000 |
39,980 |
|
- |
|
| Jones Steven C |
Director |
– • – |
2020-12-10 |
4 |
S |
$50.30 |
$1,006,000 |
I/I |
(20,000) |
1,050,000 |
|
0% |
|
| Jones Steven C |
Director |
– • – |
2020-12-07 |
4 |
S |
$49.45 |
$2,257,788 |
I/I |
(45,658) |
1,070,000 |
|
2% |
|
| Jones Steven C |
Director |
– • – |
2020-12-04 |
4 |
S |
$48.07 |
$3,095,420 |
I/I |
(64,394) |
1,115,658 |
|
-3% |
|
| Johnson Kevin C |
Director |
– • – |
2020-12-04 |
4 |
S |
$47.88 |
$1,181,822 |
D/D |
(24,683) |
30,983 |
|
-3% |
|
| Jones Steven C |
Director |
– • – |
2020-12-03 |
4 |
S |
$48.03 |
$958,102 |
I/I |
(19,948) |
1,180,052 |
|
-3% |
|
| Bonello William |
President, Informatics |
• – – |
2020-12-02 |
4 |
S |
$46.80 |
$374,400 |
D/D |
(8,000) |
12,060 |
|
-4% |
|
| Bonello William |
President, Informatics |
• – – |
2020-12-02 |
4 |
OE |
$8.03 |
$64,240 |
D/D |
8,000 |
20,060 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-11-25 |
4 |
S |
$45.48 |
$3,505,326 |
D/D |
(77,074) |
370,902 |
|
-5% |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-11-25 |
4 |
OE |
$7.52 |
$579,596 |
D/D |
77,074 |
447,976 |
|
- |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-11-24 |
4 |
S |
$45.19 |
$2,391,726 |
D/D |
(52,926) |
370,902 |
|
-4% |
|
| Cardoza George |
President, Pharma Services |
• – – |
2020-11-24 |
4 |
OE |
$7.52 |
$548,404 |
D/D |
72,926 |
423,828 |
|
- |
|
| Hipp Raymond R |
Director |
– • – |
2020-11-16 |
4 |
S |
$42.28 |
$2,959,600 |
D/D |
(70,000) |
66,800 |
|
-2% |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-11-16 |
4 |
S |
$42.34 |
$4,234,000 |
D/D |
(100,000) |
2,422,790 |
|
-2% |
|
| Van Oort Douglas M |
Chairman and CEO |
• • – |
2020-11-16 |
4 |
OE |
$7.52 |
$150,400 |
D/D |
20,000 |
2,522,790 |
|
- |
|
544 Records found
|
|
Page 6 of 22 |
|
|
0.12 (0.91%) 
